The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

Vistagen (VTGN) announced that the U.S. Patent and Trademark Office or USPTO, granted a patent to the company for its oral non-opioid product ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, ...

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central ...

the availability and scope of applicable patents; fluctuating costs of materials and other resources and services required to conduct Vistagen’s ongoing and/or planned clinical and nonclinical ...

January 10, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of ...

SOUTH SAN FRANCISCO - Vistagen Therapeutics (VTGN), a clinical-stage neuroscience company with a market capitalization of $81.58 million, has announced encouraging results from a Phase 2A study of ...

Vistagen (VTGN) announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment ...

Vistagen (NASDAQ:VTGN) reported positive results from a Phase 2a pilot study of its drug candidate PH15 in the improvement of psychomotor impairment caused by mental fatigue. The drug developer ...